The estimated Net Worth of Brenton Karl Ahrens is at least $401 Thousand dollars as of 13 September 2022. Mr. Ahrens owns over 45,000 units of Iterum Therapeutics Plc stock worth over $39,295 and over the last 19 years he sold ITRM stock worth over $238,756. In addition, he makes $122,500 as Independent Interim Chairman of the board at Iterum Therapeutics Plc.
Sign up
Mr. Ahrens ITRM stock SEC Form 4 insiders trading
Brenton has made over 4 trades of the Iterum Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 37,246 units of ITRM stock worth $67,788 on 16 September 2022.
The largest trade he's ever made was buying 506,656 units of Iterum Therapeutics Plc stock on 30 May 2018 worth over $6,586,528. On average, Brenton trades about 36,600 units every 92 days since 2005. As of 13 September 2022 he still owns at least 37,246 units of Iterum Therapeutics Plc stock.
You can see the complete history of Mr. Ahrens stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brenton Ahrens biography
Brenton K. Ahrens serves as Independent Interim Chairman of the board of the Company. Since 1999, Mr. Ahrens has served as a general partner with Canaan Partners LLP, a venture capital firm. Prior to joining Canaan Partners, Mr. Ahrens worked in both commercial and technical roles at General Surgical Innovations, a biotechnology company, Ethicon (J&J), a medical device company, and IAP Research, an engineering company. Mr. Ahrens previously served on the board of directors of Durata Therapeutics, Inc., and continues to serve on a number of other private pharmaceutical and healthcare company boards. Mr. Ahrens holds a B.S. and an M.S. in mechanical engineering from the University of Dayton and an M.B.A. from the Tuck School of Business at Dartmouth College.
What is the salary of Brenton Ahrens?
As the Independent Interim Chairman of the board of Iterum Therapeutics Plc, the total compensation of Brenton Ahrens at Iterum Therapeutics Plc is $122,500. There are 7 executives at Iterum Therapeutics Plc getting paid more, with Corey Fishman having the highest compensation of $1,392,030.
How old is Brenton Ahrens?
Brenton Ahrens is 57, he's been the Independent Interim Chairman of the board of Iterum Therapeutics Plc since 2019. There are 3 older and 9 younger executives at Iterum Therapeutics Plc. The oldest executive at Iterum Therapeutics Plc is Dr. Michael W. Dunne M.D., 61, who is the Strategic Advisor & Director.
What's Brenton Ahrens's mailing address?
Brenton's mailing address filed with the SEC is 285 Riverside Ave # 250, Westport, CT 06880, USA.
Insiders trading at Iterum Therapeutics Plc
Over the last 6 years, insiders at Iterum Therapeutics Plc have traded over $51,533,386 worth of Iterum Therapeutics Plc stock and bought 4,586,895 units worth $57,505,095 . The most active insiders traders include Capital Management, L.P.Ra ..., Alexander J Sarissa Capital..., and James Healy. On average, Iterum Therapeutics Plc executives and independent directors trade stock every 38 days with the average trade being worth of $474,585. The most recent stock trade was executed by Michael W. Dunne on 6 August 2024, trading 106,247 units of ITRM stock currently worth $112,091.
What does Iterum Therapeutics Plc do?
iterum therapeutics plc is an ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. these products are aimed at combatting the global crisis of multi-drug resistant (mdr) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. for more information on iterum therapeutics please visit www.iterumtx.com.
What does Iterum Therapeutics Plc's logo look like?
Complete history of Mr. Ahrens stock trades at Dexcom Inc and Iterum Therapeutics Plc
Iterum Therapeutics Plc executives and stock owners
Iterum Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Corey Fishman,
Chief Executive Officer, Director -
Corey N. Fishman,
Pres, CEO & Director -
Michael Dunne,
Chief Scientific Officer -
Judith Matthews,
Chief Financial Officer -
Judith M. Matthews,
Chief Financial Officer -
Dr. Michael W. Dunne M.D.,
Strategic Advisor & Director -
Dr. Sailaja Puttagunta M.D.,
Chief Medical Officer -
Brenton Ahrens,
Independent Interim Chairman of the board -
Shahzad Malik,
Independent Director -
David Kelly,
Independent Director -
Ronald Hunt,
Independent Director -
Patrick Heron,
Independent Director -
Mark Chin,
Independent Director -
Dr. Steven I. Aronin M.D.,
Sr. VP & Head of Clinical Devel. -
Louise Barrett,
Sr. VP of Legal Affairs & Sec. -
Tom Loughman Ph.D.,
Sr. VP of Technical Operations -
Beth Hecht,
Director -
Vijay K Ratcliffe Liam Lathi,
-
Venture Partners Ix, L.P.Po...,
-
James Healy,
Director -
X L.P.Canaan Partners X Llc...,
-
Paul R Edick,
Director -
Jeffrey R. Schaffnit,
Chief Commercial Officer -
Patrick J Heron,
Director -
Capital Management, L.P.Ra ...,
-
Healthcare Vii, L.P.Frazier...,
-
Venture Partners Ix, L.P.So...,
-
Venture Partners Ix, L.P.So...,
-
Alexander J Sarissa Capital...,
-
Sailaja Puttagunta,
Chief Medical Officer